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OBJECTIVES We sought to characterize natriuretic peptide levels in a cohort of rigorously characterized
subjects with lone atrial fibrillation (AF).
BACKGROUND Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are sensitive biomarkers
of cardiac contractile dysfunction. Both peptides have been reported to be elevated in cohorts
with AF, but previous studies have included subjects with underlying structural heart disease.
We studied these hormones in 150 subjects with lone AF.
METHODS Study subjects had electrocardiographic evidence of at least one episode of AF and a
structurally normal heart on echocardiography. Subjects were excluded if they had a history
of a myocardial infarction, rheumatic heart disease, cardiomyopathy, significant valvular
disease, hyperthyroidism, or hypertension that preceded the onset of AF. Control subjects
were obtained from a healthy outpatient primary care population. Plasma pro-ANP and
N-terminal pro-BNP (nt-pro-BNP) levels were determined using commercially available
immunoassays.
RESULTS A total of 150 serial subjects with lone AF were enrolled and studied, the majority during
normal sinus rhythm. Median levels of nt-pro-BNP were significantly elevated in subjects
with lone AF as compared with control subjects (166 vs. 133 fmol/ml, p  0.0003). There
was no significant difference in pro-ANP levels between subjects with lone AF and control
subjects (1,730 vs. 1,625 fmol/ml, p  0.90).
CONCLUSIONS Discordant natriuretic peptide levels were observed in this homogeneous population of
subjects with lone AF. This biomarker pattern, which is present even in sinus rhythm, may
represent an underlying subclinical predisposition to this common arrhythmia. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.045Cardiol 2005;45:82–6) © 2005 by the American College of Cardiology Foundation
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fitrial fibrillation (AF) is the most common clinical arrhyth-
ia, as well as an important source of morbidity and
ortality (1). The primary pathophysiology of AF is ob-
cured by the secondary effects of the arrhythmia itself (2).
eritable forms of AF suggest that some individuals have
n intrinsically lower threshold for developing this arrhyth-
ia (3). Such a diathesis might take the form of pulmonary
enous abnormalities (4), subclinical myocardial disease (5),
r isolated disturbances of atrial electrophysiology (2).
In searching for biomarkers of a predisposition to AF, we
ypothesized that a diathesis toward this arrhythmia might
e reflected in abnormalities of the natriuretic peptide (NP)
xis, as atrial structure and function are central to both the
fferent and efferent limbs of this endocrine pathway (6).
he NP hormones are secreted in response to several
timuli, including intracardiac pressure, and have become
opular candidates for the noninvasive assessment of cardiac
ysfunction (6,7). Previous studies of the NP axis in AF
ave included subjects with a wide variety of etiologies for
heir arrhythmia (8–10). To limit the role of potential
onfounders, we studied pro-atrial natriuretic peptide
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ccepted September 2, 2004.ANP) andN-terminal-pro-brain natriuretic peptide (BNP) in
ubjects with rigorously defined lone AF.
We have identified a significant elevation in plasma
t-pro-BNP levels in subjects with lone AF. This elevation
s present when subjects are in sinus rhythm. Interestingly,
ro-ANP levels were not elevated, discordant with the
t-pro-BNP results. These data suggest that the combina-
ion of elevated nt-pro-BNP and normal pro-ANP levels is
ssociated with lone AF and may prove to be a marker of an
nderlying predisposition to this arrhythmia.
ETHODS
tudy population. All studies were performed with Insti-
utional Review Board approval at Massachusetts General
ospital and with written, informed consent from each
ubject. Individuals were eligible for enrollment if they had
t least one documented electrocardiogram (ECG) with AF
nd a structurally normal heart on echocardiogram. Subjects
ere excluded if they had a history of myocardial infarction,
heumatic heart disease, cardiomyopathy, significant valvu-
ar disease, or hyperthyroidism. Subjects reporting a diag-
osis of hypertension within two years of the onset of AF
lso were excluded.
One hundred and fifty-eight subjects with lone AF were
nrolled between July 5, 2001, and May 14, 2003. Seventy-
ve control subjects, matched for age, gender, and ethnicity,
ere selected from a healthy primary care population (from
t
b
C
e
m
g
w
j
9
p
a
Q
B
s
e
e
P
u
w
V
s
W
i
B
c
a
8
e
s
a
w
S
p
a
p
r
m
a
w
C
R
B
s
d
b
S
l
m
s
y
y
w
e
w
p
w
4
w
m
t
o
e
T
F
B
M
M
P
D
a

83JACC Vol. 45, No. 1, 2005 Ellinor et al.
January 4, 2005:82–6 Natriuretic Peptides in Lone AFhe Global Repository, Genomics Collaborative, Inc., Cam-
ridge, Massachusetts).
linical characteristics. Each subject underwent a physical
xamination and a structured interview to elicit a detailed
edical history, medications, symptoms, and possible trig-
ers for AF. The medical history of all first-degree relatives
as obtained using a standardized questionnaire. All sub-
ects with lone AF had an ECG and echocardiogram within
0 days of enrollment. Echocardiography included a com-
rehensive two-dimensional, M-mode, and Doppler evalu-
tion; ejection fraction was estimated using the modified
uinones method.
lood sampling and natriuretic hormone assays. Blood
amples were obtained in EDTA from each subject at
nrollment. Samples were centrifuged, and plasma was
xtracted, aliquoted, and stored at 80°C until analysis.
lasma pro-ANP and nt-pro-BNP levels were determined
sing commercially available enzyme immunoassays
ithout extraction (manufactured by Biomedica Gruppe,
ienna, Austria), according to the manufacturer’s in-
tructions, with a Victor-3 plate reader (Perkin-Elmer,
ellesley, Massachusetts).
The immunoassay for nt-pro-BNP employs an
mmunoaffinity-purified sheep antibody specific for nt-pro-
NP (amino acids 8–29). The pro-ANP assay consists of a
apture antibody specific for pro-ANP (amino acids 10–19)
nd a detection antibody specific for pro-ANP (amino acids
5–90). For each assay, the cross reactivity with other NP
pitopes is 1%. Assays were performed in duplicate in a
ingle run and normalized to a standard curve. Intra-assay
nd inter-assay variances for pro-ANP and nt-pro-BNP
ere all 7%.
tatistical analysis. Baseline and transformed values of
ro-ANP and nt-pro-BNP were highly skewed in patients
nd control subjects. The NP levels were therefore com-
ared in patients and control subjects by using the Wilcoxon
ank-sum test. Normally distributed values are displayed as
ean values with standard deviations, whereas for pro-ANP
nd nt-pro-BNP, the median values are provided. Data
ere analyzed using Intercooled Stata 8.0 (Stata Corp.,
ollege Station, Texas).
ESULTS
aseline characteristics. During the study period, 158
ubjects with lone AF were enrolled. Eight subjects who
eveloped structural heart disease after the onset of AF but
efore study enrollment were excluded from analysis.
Abbreviations and Acronyms
AF  atrial fibrillation
ANP  atrial natriuretic peptide
BNP  brain natriuretic peptide
NP  natriuretic peptideeventy-five control subjects were matched to subjects with none AF based on age, gender, race, and ethnicity. Body
ass index and systolic and diastolic blood pressures were
imilar between patients and control subjects (Table 1).
The mean age at diagnosis with AF was 44.8  11.9
ears, and the mean age at enrollment was 53.8  10.7
ears. As observed in other cohorts with lone AF, subjects
ere predominately male (80.8%) (11). At the time of
nrollment, 130 subjects had paroxysmal AF and 20 subjects
ere in permanent AF (Table 2). Of those subjects with
aroxysmal AF, 111 (85%) were in sinus rhythm, 8 (6%)
ere in AF, 7 (5%) were in atrial flutter, and the remaining
(3%) were either paced or in another rhythm. Subjects
ith lone AF were receiving a variety of medications for
anagement of AF, whereas control subjects were not
aking any cardiovascular medications.
Although 23% of subjects in sinus rhythm had evidence
f left atrial enlargement on the ECG, there were no other
lectrocardiographic abnormalities. Echocardiography was
able 1. Baseline Characteristics of Subjects With Lone Atrial
ibrillation and Controls
LAF Group
(n  150)
Control
Group
(n  75)
aseline characteristics
Number
Men 121 (80.8) 60 (80.0)
Age at enrollment (yrs) 53.8  10.7 54.3  10.3
BMI 27.2  4.3 26.9  4.4
Systolic blood pressure (mm Hg) 124.2  14.7 126.7  9.0
Diastolic blood pressure (mm Hg) 76.1  8.6 77.7  7.5
Race and ethnicity
Caucasian 147 (98.0) 72 (96.0)
Hispanic 1 (0.67) 1 (1.3)
African American 1 (0.67) 1 (1.3)
Asian 1 (0.67) 1 (1.3)
edical history of probands
Pacemaker 8 (5.3) 0
HTN developed after AF 13 (8.7) 0
Development of HTN after
AF (yrs)
13.2  11.2 —
Diabetes mellitus developed
after AF
6 (3.8) 0
edications
Beta-blocker 81 (54.0) 0
Digoxin 29 (19.3) 0
Calcium-channel blocker 28 (18.7) 0
Lipid-lowering agent 14 (11.5) 0
ACE inhibitor or ARB 10 (6.7) 0
ersonal history of AF
Age at first diagnosis of AF (yrs) 44.8  11.9 —
Over 100 episodes of AF 78 (57.8) —
Paroxysmal AF at initial
presentation
141 (94.0) —
Paroxysmal AF at study
enrollment
130 (86.7) —
History of electrical cardioversion 48 (32.0) —
ata are presented as the number (percentage) or mean value  SD.
ACE  angiotensin-converting enzyme; AF  atrial fibrillation; ARB 
ngiotensin receptor blocker; BMI  body mass index; HTN  hypertension; LAF
lone atrial fibrillation.otable for a mean left atrial diameter at the upper limits of
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arameters, including chamber dimensions, wall thick-
esses, and functional indexes, were normal in the study
ohort. Control subjects had no significant medical history.
atriuretic hormone levels. Median nt-pro-BNP levels
ere significantly elevated in subjects with lone AF, as com-
ared with matched control subjects (166 vs. 133 fmol/ml, p
.0003) (Fig. 1A). The nt-pro-BNP levels in those with
ermanent AF were also significantly higher than those in
ubjects whose arrhythmia remained paroxysmal (189 vs. 157
mol/ml, p  0.0015) (Fig. 2A). Among subjects who pre-
ented with paroxysmal AF, nt-pro-BNP levels were higher in
hose individuals who progressed from paroxysmal to perma-
ent AF (197 vs. 163 fmol/ml, p  0.05).
There was no significant difference in pro-ANP levels
etween patients with lone AF and healthy control subjects
1,730 vs. 1,625 fmol/ml, p  0.90) (Figs. 1B and 2B).
owever, pro-ANP levels were significantly higher in
ubjects who developed hypertension after the onset of AF
3,764 vs. 1,622 fmol/ml, p  0.01). A negative correlation
as noted between pro-ANP and diastolic blood pressure
r  0.22, p  0.01).
A discordant pattern of nt-pro-BNP elevation (p 
.004) with normal pro-ANP levels (p  0.57) was present,
ven when all subjects in AF or in paced rhythm at the time
f measurement were excluded (Figs. 2A and 2B). The
esults were also unaffected by the exclusion of those
ubjects taking beta-blockers (data not shown).
ISCUSSION
atriuretic peptides in structural heart disease. The
atriuretic hormone axis is the best characterized cardiac
ndocrine pathway. This family of short peptides share
everal physiologic actions, including natriuresis, vasodila-
able 2. Electrocardiographic and Echocardiographic
haracteristics of Subjects With Lone Atrial Fibrillation
lectrocardiogram
Normal sinus rhythm 61 (41.0)
Sinus bradycardia 50 (33.3)
Atrial fibrillation 23 (15.3)
Atrial flutter 7 (4.7)
Paced or other rhythm 9 (6.0)
Mean ventricular rate (beats/min) 66.8 17
P-R interval (ms) 174.3 32
QRS interval (ms) 91.6 11
QTc interval (ms) 405.0 40
Axis 33.5 36
Left atrial enlargement 27 (23.9)
Left ventricular hypertrophy 6 (4.2)
chocardiogram
Ejection fraction (%) 62.0 6.3
Left atrial size (mm) 38.7  6.5
Left ventricular internal dimension (mm) 49.4 6.3
Aortic root (mm) 32.8 7.1
Posterior wall thickness (mm) 9.8 1.2
Interventricular septal wall thickness (mm) 10.0 1.6
ata are presented as the number (percentage) or mean value  SD.ion, and the modulation of central and peripheral barore-
c
texes (6). Each active peptide is cleaved from the
-terminus of a longer precursor, and although the biologic
oles of the N-terminal fragments are unknown, the kinetics
f these pro-peptides make them more suitable for use as
iomarkers (12). Both ANP and BNP are coordinately
egulated in a wide range of clinical conditions associated
ith abnormalities of systolic or diastolic function. Elevated
irculating levels of these peptides have been correlated with
ymptoms and adverse clinical outcomes in congestive heart
ailure (7). The utility of the NPs as a screening tool for left
entricular function (13), a diagnostic adjunct in the evalu-
tion of dyspnea, or as a therapeutic end point in heart
ailure, is under investigation (7).
atriuretic peptides in AF. Elevated levels of both ANP
nd BNP have been described in several different AF
ohorts. In congestive heart failure, where NP levels are
lready markedly elevated, the onset of AF is associated
ith a further increase (8,14). ANP and BNP each have
een reported as elevated both in paroxysmal and perma-
ent AF (6,8). Although in several studies, NP levels
ecreased after return to sinus rhythm, there also seems to
e a slow attenuation of the initial elevation of ANP over
ime with sustained AF (15). This pattern of release is
onsistent with the known response characteristics of ANP,
hich is only transiently elevated after acute stimuli but is
ersistently elevated with chronic stimuli. This is thought to
e a result of rapid release from a finite pool of storage
igure 1. Box plots illustrating the median levels of nt-pro-brain natri-
retic peptide (nt-proBNP) (A) and pro-atrial natriuretic peptide
proANP) (B) in subjects with lone atrial fibrillation (LAF) and in healthy
ontrol subjects. Boxes show interquartile ranges, and the bars represent
he 10th and 90th percentiles.
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January 4, 2005:82–6 Natriuretic Peptides in Lone AFesicles in the acute setting, whereas chronic disease states
nduce increased messenger ribonucleic acid and peptide
ynthesis expanding the storage pool (6). The late attenua-
ion in permanent AF has been attributed to the trophic
onsequences of persistent arrhythmia, but, so far, there are
ew data on the nature of such endocrine remodeling (16).
ll of these observations are potentially confounded by the
nown effects of structural heart disease on the NPs. Atrial
brillation is a highly heterogeneous condition, and it has
roven difficult to dissociate the effects of the arrhythmia
rom those of the underlying disorders (1).
Approximately 20% to 30% of AF occurs in the absence
f any objective evidence of structural heart disease and is
nown as lone AF (11). To avoid the confounding effects of
nderlying structural heart disease, we compared the levels
f pro-ANP and nt-pro-BNP in subjects with rigorously
efined lone AF and in healthy control subjects. Our data
uggest that lone AF, unlike other forms of the arrhythmia,
s associated with a unique pattern of ANP and BNP
elease. In contrast to previous studies of the NPs, we
dentified discordant regulation of the BNP and ANP axes,
ith a significant elevation of nt-pro-BNP in the presence
igure 2. Box plot illustrating the median level of nt-pro-brain natriuretic
ontrols subjects versus patients with paroxysmal or permanent lone atrial
o the rhythm at the time of sampling. Boxes show interquartile ranges, and
ignificant difference between any of the groups. AFl  atrial flutter; NSRf normal pro-ANP levels in subjects with a history of lone mF. These findings were unrelated to the current rhythm of
he study subjects (Fig. 2A).
ossible mechanisms of discordant regulation of
Ps. Release of ANP and BNP may be uncoupled in some
xperimental situations. Hypertrophic stimuli, including
ndothelin-1 and phenylephrine, differentially induce ANP
nd BNP in in vitro models (17), but whether these stimuli
esult in abnormal circulating NP levels before any hemo-
ynamic perturbation is not known. Secretion of ANP and
NP is distinctively regulated in different tissues, and the
otential contributions of various sources to circulating
lasma levels under pathologic conditions may vary (6).
inally, the NP pathways intersect at many levels with other
euroendocrine, paracrine, or autocrine pathways, whose
ardiac effects are less well defined and may have differential
ffects on ANP and BNP (6). It remains to be seen whether
he source of BNP in subjects with lone AF is atrial,
entricular, or extracardiac.
Although the fundamental mechanisms of isolated BNP
levation remain uncertain, recent population data have iden-
ified BNP as a predictor of specific cardiovascular end points.
evels of nt-pro-BNP may predict the subsequent develop-
ide (nt-proBNP) (A) and pro-atrial natriuretic peptide (pro-ANP) (B) in
ation (AF). Subjects with paroxysmal AF (PAF) were stratified according
ars represent the 10th and 90th percentiles. In B, there was no statistically
ormal sinus rhythm; SB  sinus bradycardia.pept
fibrillent of AF, hypertension, stroke, and congestive heart failure
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Natriuretic Peptides in Lone AF January 4, 2005:82–618); however, the temporal relationship between these disor-
ers varies, raising the possibility that these phenotypes repre-
ent distinct manifestations of a common etiology character-
zed by abnormal BNP levels. Our data support this
ypothesis. Theoretically, dysregulation of the NP axis may be
pstream of AF, as BNP is known to potentiate vagal efferent
ctivity, thus sustaining fibrillatory rotors (19). Brain natri-
retic peptide is also coupled to several ionic currents, but there
s no evidence of increased automaticity with this peptide, as
here is with ANP (6). A more likely unifying hypothesis is
hat elevated BNP is simply a marker for a subset of AF
atients with a primary disorder predisposing not only to the
aintenance of AF, but also to subsequent hypertension,
troke, and heart failure. Detailed longitudinal investigation of
ubjects with lone AF will help clarify these potential relation-
hips and explore the precise mechanisms for uncoupling ANP
nd BNP.
tudy limitations. The current study is based in a tertiary-
are arrhythmia clinic and may be prone to referral bias. The
ohort demographics are comparable to those of previous
one AF studies, and these individuals are of largely North-
rn European descent. It will be important to replicate our
ndings in ethnically, racially, and geographically distinct
opulations.
onclusions. We have identified a particular pattern of
iscordant ANP and BNP levels that is associated with lone
F. This discordance may reflect the differential sensitivities of
he ANP and BNP pathways to the primary process in AF.
urther work will be required to dissect the link between
bnormal expression and secretion of these peptides and the
isk of AF. The definition of specific biomarker profiles,
ossibly incorporating the NPs, will be an important step in
issecting the etiology of AF. These findings emphasize the
eed for detailed clinical investigation in the evaluation of
merging biomarkers.
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